Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor containing regimen

DSpace/Manakin Repository

Show simple item record Conesa-Botella, A. Florence, E. Lynen, L. Colebunders, R. Menten, J. Moreno-Reyes, R. 2010-12-17T10:35:58Z 2010-12-17T10:35:58Z 2010
dc.identifier.issn 1742-6405
dc.identifier.other ITG-C1B
dc.identifier.other ITG-C2A
dc.identifier.other ITG-C3A
dc.identifier.other ITG-C4A
dc.identifier.other ITG-I5A
dc.identifier.other CLINIC
dc.identifier.other U-HIVCLI
dc.identifier.other DOI
dc.identifier.other URL
dc.identifier.other FTA
dc.identifier.other Abstract
dc.identifier.other Electronic
dc.identifier.other UPD28
dc.description.abstract BACKGROUND: Vitamin D is an important determinant of bone health and also plays a major role in the regulation of the immune system. Interestingly, vitamin D status before the start of highly active antiretroviral therapy (HAART) has been recently associated with HIV disease progression and overall mortality in HIV-positive pregnant women. We prospectively studied vitamin D status in HIV individuals on HAART in Belgium. We selected samples from HIV-positive adults starting HAART with a pre-HAART CD4 T-cell count >100 cells/mm3 followed up for at least 12 months without a treatment change. We compared 25-hydroxyvitamin D plasma [25-(OH)D] concentration in paired samples before and after 12 months of HAART. 25-(OH)D levels are presented using two different cut-offs: <20 ng/ml and <30 ng/ml. RESULTS: Vitamin D deficiency was common before HAART, the frequency of plasma 25-(OH)D concentrations below 20 ng/ml and 30 below ng/ml was 43.7% and 70.1% respectively. After 12 months on HAART, the frequency increased to 47.1% and 81.6%. HAART for 12 months was associated with a significant decrease of plasma 25-(OH)D concentration (p=0.001). Decreasing plasma 25-(OH)D concentration on HAART was associated in the multivariate model with NNRTI-based regimen (p=0.001) and lower body weight (p=0.008). Plasma 25-(OH)D concentrations decreased significantly in both nevirapine and efavirenz-containing regimens but not in PI-treated patients. CONCLUSIONS: Vitamin D deficiency is frequent in HIV-positive individuals and NNRTI therapy further decreases 25-(OH)D concentrations. Consequently, vitamin D status need to be checked regularly in all HIV-infected patients and vitamin D supplementation should be given when needed en
dc.language English en
dc.subject Viral diseases en
dc.subject HIV en
dc.subject AIDS en
dc.subject HAART en
dc.subject Antiretrovirals en
dc.subject Regimens en
dc.subject Non-nucleoside en
dc.subject Reverse transcriptase inhibitors en
dc.subject Vitamin D en
dc.subject Deficiency en
dc.subject Bone mineral density en
dc.subject CD4 lymphocyte count en
dc.subject Cohort studies en
dc.subject Nevirapine en
dc.subject Efavirenz en
dc.subject Cholesterol en
dc.subject Associations en
dc.subject Body weight en
dc.subject Belgium en
dc.subject Europe, West en
dc.title Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor containing regimen en
dc.type Article-E en
dc.citation.issue 40 en
dc.citation.jtitle AIDS Research and Therapy en
dc.citation.volume 7 en
dc.citation.jabbreviation AIDS Res Ther en

Files in this item

This item appears in the following Collection(s)

Show simple item record